EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK to supply additional data for breast cancer drug; panel okays generics for Roche’s CellCept.
You may also be interested in...
EU Pharma Denies Skirting Rules On Pediatric Cancer Drug Development
The European pharmaceutical industry has refuted claims that manufacturers are exploiting a loophole in EU legislation to avoid running non-lucrative trials for pediatric oncology drugs.
European Regulatory Updates, In Brief
Pharming obtains positive opinion for its HAE therapy: Pharming's Ruconest (conestat alfa), a human recombinant protein extracted from the milk of transgenic rabbits, was recommended for approval by the European Medicines Agency for the acute treatment of angioedema attacks in patients with hereditary angioedema (HAE). The orphan product, a recombinant human C1 esterase inhibitor formerly known as Rhucin, will be marketed by two partners - Dr Esteve in Spain, Portugal, Greece and Andorra, and Swedish Orphan Biovitrum in all other EU countries as well as Iceland, Norway and Liechtenstein. Pharming estimates the current value of the European HAE market at €110 million ($136 million). Ruconest previously was rejected by the Committee for Medicinal Products for Human Use in December 2007, when it said there was insufficient data to support its approval (1"The Pink Sheet" DAILY, Dec. 14, 2007). The company refiled the product with additional data from a recently completed North American Phase III trial
European Regulatory Updates, In Brief
Pharming obtains positive opinion for its HAE therapy: Pharming's Ruconest (conestat alfa), a human recombinant protein extracted from the milk of transgenic rabbits, was recommended for approval by the European Medicines Agency for the acute treatment of angioedema attacks in patients with hereditary angioedema (HAE). The orphan product, a recombinant human C1 esterase inhibitor formerly known as Rhucin, will be marketed by two partners - Dr Esteve in Spain, Portugal, Greece and Andorra, and Swedish Orphan Biovitrum in all other EU countries as well as Iceland, Norway and Liechtenstein. Pharming estimates the current value of the European HAE market at €110 million ($136 million). Ruconest previously was rejected by the Committee for Medicinal Products for Human Use in December 2007, when it said there was insufficient data to support its approval (1"The Pink Sheet" DAILY, Dec. 14, 2007). The company refiled the product with additional data from a recently completed North American Phase III trial